Value-Based Pricing: L’Enfant Terrible?

Sarah Garner1, Andrew Rintoul1, Suzanne Hill2
1Innovation, Access and Use, Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland
2Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland

Tóm tắt

Từ khóa


Tài liệu tham khảo

Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2008;373(9659):240–9. https://doi.org/10.1016/S0140-6736(08)61762-6 .

Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016. https://doi.org/10.1371/journal.pmed.1002032 .

Towse A, Barnsley P. Approaches to identifying, measuring, and aggregating elements of value. Int J Technol Assess Health Care. 2013;29(4):360–4. https://doi.org/10.1017/S0266462313000524 .

Neyt M. Value-based pricing: do not throw away the baby with the bath water. PharmacoEconomics. 2017. https://doi.org/10.1007/s40273-017-0566-5 .

Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000;283(16):2116–21.

Yong JHE, Beca J, Hoch JS. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada. PharmacoEconomics. 2013;31(3):229–36. https://doi.org/10.1007/s40273-012-0022-5 .

Summary of a workshop to inform the research agenda on improving cross-sector comparisons using QALYs and other measures. London: National Institute for Health and Care Excellence. https://www.nice.org.uk/Media/Default/About/what-we-do/science-policy-and-research/beyond_qaly_workshop_report.pdf . Accessed 3 Aug 2017.

Bertram MY, Lauer JA, de Joncheere K, Edejer T, Hutubessy R, Kieny MP, Hill SR. Cost-effectiveness thresholds: pros and cons. Bull World Health Org. 2016;94:925–30. https://doi.org/10.2471/BLT.15.164418 .

Garner S. How does NICE value innovation? Drug Dev Res. 2010;71:449–56. https://doi.org/10.1002/ddr.20423 .

Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet. 2017;389:403–76.

World Health Organisation. FAIR PRICING FORUM 2017 MEETING REPORT. 2017. http://www.who.int/medicines/access/fair_pricing/FairPricingForum2017MeetingReport.pdf?ua=1 . Accessed 7 Nov 2017.